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It has been well established that lung mucociliary clearance is depressed in patients with chronic obstructive 
pulmonary disease. This study examines whether oral antibiotics have a detectable effect on this clearance 
mechanism during exacerbation in patients with such disease. Twelve patients with a mean f SE age of 63 & 2 years 
participated in a randomized, double-blind, parallel group study to assess the effect of 1 week of treatment with 
amoxycillin (500 mg t.d.s.) or ciprofloxacin (500 mg b.d.) on lung mucociliary clearance during exacerbation. Lung 
mucociliary clearance rates were measured by a non-invasive radioaerosol technique. Both drugs on average resulted 
in small, non-significant, enhancement of mucociliary clearance. Following treatment, the numbers of coughs were 
reduced in both groups and significantly (PcO.05) after treatment with ciprofloxacin. Sputum production was also 
significantly reduced (PcO.01) in both groups. The magnitude of improvement in lung mucociliary clearance was 
relatively modest following 1 week of treatment with either antibiotic. Since the number of coughs was significantly 
less after ciprofloxacin treatment the measured enhancement of lung mucociliary transport is probably, however, an 
underestimate. 
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Introduction 
The lung’s main function of gas exchange constantly 
exposes the respiratory mucosa to noxious substances and 
potentially harmful agents inhaled from the environment. 
Despite this, the respiratory tract is kept sterile in healthy 
subjects by the mucociliary clearance system which forms 
the first-line defence mechanism of the bronchial tree (1). 
An effective mucociliary clearance mechanism depends on 
the intricate interrelationship between the integrity of the 
ciliated epithelium, the ciliary beat frequency and coordi- 
nation, the consistency and thickness of the watery precili- 
ary layer in which the cilia are immersed and the quantity 
and rheological and biochemical properties of the epiphase 
(gel) layer of secretions overlying the tips of the cilia (2). 
If lung mucociliary clearance transport deteriorates, as is 
the case in patients with chronic obstructive pulmonary 
disease (3,4), the ciliated epithelium not only loses it 
protective role but contributes to the pathophysiological 
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manifestations of the clinical syndrome. In such conditions 
cough comes into action as a back-up mucus clearance 
mechanism (5). 
Exacerbations of chronic obstructive pulmonary disease 
(COPD) are characterized by increases in dyspnoea, cough, 
and sputum production (6). It is commonly recommended 
that these exacerbations should be treated with a course of 
antibiotics for 7-10 days (7-9). Because COPD is a com- 
mon disease, and patients are reported to have an average 
of one to four exacerbations per year, antibiotic therapy for 
these exacerbations is a frequently used treatment. 
Some antibiotics have been shown to have an inhibitory 
effect on ciliary activity (10-13) whereas others have no 
such effect (12,14). 
There is, to date, no information regarding the effect of 
oral antibiotics on lung mucociliary clearance. We therefore 
investigated the effect of two antibiotics, amoxycillin and 
ciprofloxacin, on lung mucociliary function in patients with 
chronic obstructive airway disease. 
Methods 
PATIENTS 
Twelve patients (nine men, three women) with COPD were 
studied during exacerbation. The mean f SE age and height 
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TABLE 1. Mean f SE physical characteristics and tobacco 
consumption for the two groups of patients who were 
treated with either amoxycillin (AM) or ciprofloxacin (CP) 
Groups 
AM CP 
No. of patients 6 6 
Sex 4 M, 2 F 5 M, 1 F 
Age (years) 63 zt 3 63 f 3 
Height (m) 1.67 f 0.05 1.70 f 0.03 
Tobacco consumption* (pack yr) 21.9 f 6.7 17.5 * 4.1 
*Four ex-smokers in the AM group and five ex-smokers in 
the CP group. 
of the patients were 63 f 2 years and 1.69 f 0.03 m respect- 
ively. Three patients were lifelong non-smokers and the 
remaining nine patients were ex-smokers with a mean f SE 
tobacco consumption of 19.5 f 3.6 pack yr. 
All 12 patients were receiving treatment with inhaled 
bronchodilators and corticosteroids; seven were taking 
inhaled anticholinergic drugs, and five were maintained 
with oral corticosteroid therapy. Six of the patients were 
also receiving treatment with oral bronchodilators (four 
@,-agonist and two methylxanthines). 
All patients completed the 7 day treatment phase of the 
study; six patients additionally completed a follow-up phase 
(3 weeks later). Five patients withdrew during the follow-up 
phase in the ciprofloxacin group owing to concurrent illness 
(three patients experienced an exacerbation of their COAD 
requiring hospitalization and two patients for lack of 
efficacy as they required further treatment) and one patient 
in the amoxycillin group was lost to follow-up. 
The mean f SE physical characteristics and tobacco 
consumption for the two groups [amoxycillin (AM) and 
ciprofloxacin (CP)] are given in Table 1. There were no 
significant differences between the two groups for any of 
the variables and hence the AM and CP groups were 
considered to be comparable. 
STUDY DESIGN 
The study was designed in a randomized, double-blind, 
parallel group manner. Patients presenting to the clinic with 
an exacerbation of their COPD and who volunteered to 
participate had pulmonary function and lung mucociliary 
clearance measured (baseline) before being allocated to 
one of two treatment groups receiving either oral 
amoxycillin 500 mg t.d.s. or oral ciprofloxacin 500 mg b.d. 
for 7 days. 
Each patient attended the laboratories for a second 
(identical) assessment at the end of the 7 day treatment 
period. Six patients attended for a third assessment after 
3 weeks from the end of treatment, as a follow-up phase. 
The patients were asked to refrain from taking any 
inhaled bronchodilators for at least 6 h before each 
assessment and to collect their sputum over a period of 24 h 
prior to each assessment. 
Informed written consent was obtained from each patient 
and the study was approved by the hospital’s ethical 
practices subcommittee. 
MUCOCILIARY CLEARANCE 
An objective, non-invasive, radioaerosol technique, which 
has previously been described in detail, was used to measure 
lung mucociliary clearance (15). Polystyrene particles, 5 pm 
in diameter, were firmly labelled with the radionuclide 
99Tcm (16). The radioaerosol was inhaled, under strictly 
controlled conditions, through the mouth while the patients 
were seated. Discrete breaths of 0.45 1 were taken by each 
patient from the resting level of the lungs and followed by a 
3 s breath hold pause to enhance, by sedimentation, the 
peripheral deposition of the radioaerosol within the lungs 
(17). After the inhalation of the radioaerosol particles, 
the patients gargled and drunk some water to clear any 
remaining particles from the oropharynx and oesophagus. 
Particles were measured by two axially opposed scintil- 
lation detectors placed midway along the sternum antero- 
posteriorly to the chest. The detectors were collimated so 
that the field of view included most of both lungs but 
virtually excluded the stomach (18). Counts were taken at 
half-hourly intervals for 6 h after the inhalation of the 
radioaerosol and a final count at 24 h. All counts were 
corrected for radioactive background and physical decay of 
the radionuclide and expressed as a percentage of the initial 
count to overcome unavoidable differences in the initial 
radioactive lung burden. 
The amount of radioaerosol remaining in the lung at 24 h 
was used to estimate alveolar deposition (AD) which is 
taken as being the proportion of the radioaerosol particles 
deposited beyond the ciliated airways and thus not avail- 
able for mucociliary clearance (19). Subtracting the AD 
from the total lung burden yielded a tracheobronchial 
retention curve (20). Tracheobronchial clearance was 
assessed by measuring the area under the curve for the first 
3 h (AUC, X), the second 3 h (AU(&) and for the whole 
6 h observation period (AU&) (21). 
The initial topographic distribution of the radioaerosol 
particles within the lungs was assessed by a large field of 
view y camera linked to a computer for data analysis. The 
initial distribution of the particles was expressed as a 
penetration index (PI) which is the ratio of the amount of 
radioaerosol in an outer to inner region of the lungs divided 
by the same ratio of krypton (“Krm) gas (22). 
The patients were encouraged to avoid coughing during 
the 6 h observation period. Nevertheless they were unable 
to avoid some episodes of coughing. The numbers of 
involuntary coughs were therefore recorded and sputum 
samples (when produced) were collected and weighed; 
their radioactive content was measured and expressed as a 
percentage of the initial tracheobronchial deposition. This 
percentage was added back to the retention curves at the 
appropriate times of expectoration to account for the effect 
of productive coughing on mucus transport (23). 
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TABLE 2. Mean * SE percentage predicted pulmonary function indices, alveolar deposition (AD) and 
penetration indices (PI) for the two groups of patients who were treated with either amoxycilline 
(AM) or ciprofloxacin (CP) during the three study visits 
Baseline 
AM group 
7 days 30 days 
CP group 
Baseline 7 days 
FEV, 50 f 5 46 f 4 52 f 5 52 * 6 51&5 
FVC 76 zt 7 72 f 7 83 zt 9 58 f 5 58 f 5 
PEF 41*5 40+4 43 f 6 53 zt I 55*4 
MMFRsE 21*3 20&4 24 dz 5 43 * 9 42f 12 
Vmax,, 17zk4 14 f 2 19*4 24 xt I 28 zt 6 
Vmax,, 20*4 17&2 19 f 2 32 k 10 34& 11 
AD 32 + 7 33 f 1 30* 10 34 f 7 34 zt 6 
PI 0.40 h 0.06 0.34 zt 0.08 0.36 f 0.10 0.40 It 0.09 0.35 f 0.07 
PULMONARY FUNCTION 
The pulmonary function of each patient was assessed on 
each of the two (three) visits before inhalation of the 
radioaerosol particles. Forced expiratory volume in 1 s 
(FEV,), forced vital capacity (FVC) and maximum mid- 
expiratory flow rate between 25% and 75% of FVC 
(MMFz5-& were measured using a Vitalograph 
spirometer. A Wright peak flow meter was used to measure 
peak expiratory flow rate (PEF). Using an Ohio-840 
spirometer, the flow rates at 25% and at 50% of vital 
capacity (Vmax,,, Vmax,,) were measured. For each lung 
function index the highest of three technically acceptable 
measurements was recorded and expressed as a percentage 
predicted value. 
STATISTICAL ANALYSIS 
The data were analysed using the (non-parametric) paired 
and unpaired Wilcoxon tests. The level of significance was 
taken at P<O.O5. 
Results 
The mean * SE of the percentage predicted pulmonary 
function indices, alveolar deposition and penetration indi- 
ces for the AM and CP groups at baseline and at 7 and 
30 days after treatment initiation are given in Table 2. 
There were no significant differences in baseline pulmonary 
function indices between the two groups or following 
treatment compared with baseline within and between the 
two groups. The alveolar depositions and penetration indi- 
ces were similar between the within groups at all time 
points. 
Figure 1 shows the mean tracheobronchial retention 
curves, corrected for productive coughing, for the two 
groups at baseline, 7 days after treatment and 30 days after 
treatment for the AM group. The baseline tracheobronchial 
clearance was on average, but not statistically so, slower in 
the group who were subsequently treated with ciprofloxacin 
compared with the group who were treated with amoxy- 
cillin. Both drugs on average resulted in small, non- 
significant, enhancement of clearance. For the AM group 
the clearance at 30 days was no different from that at 
I days. 
The mean&s~ areas under the tracheobronchial clear- 
ance curves between 0 and 3 h (AU&) were 213% i 28%, 
207% & 32% and 204% f 30% h at baseline, 7 days and 
30 days after treatment with amoxycillin. The correspond- 
ing AUC,-, for the CP group were 246% & 13% and 
230% f 17% h at baseline and 7 days after treatment 
respectively. The AU& for the AM group were 
201 I I I I I 
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Time after inhalation of radioaerosol (h) 
FIG. 1. Mean tracheobronchial retention curves for the 
two groups of patients who were treated with either 
amoxycillin (AM) or ciprofloxacin (CP): A, AM baseline; 
0, AM 7 days; 0, AM 30 days; n , CP baseline; 0, 
CP 7 days. 
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FIG. 2. Number of coughs during 6 h observation period 
at baseline and at 7 days posttreatment in all patients. 
127% & 29%, 118% f 37% and 118% * 33% h at baseline, 
7 and 30 days respectively. The corresponding AUC,-, for 
the CP group were 157% f 19% and 140% f 17% h at 
baseline and at 7 days. 
Following 7 days of therapy the number of coughs was 
significantly reduced (WO.02) for all 12 patients as shown 
in Fig. 2; from 19 & 4 to 14 k 4 (DO.1) and from 13 * 4 to 
6 & 2 (WO.05) in the AM and CP groups respectively. At 
30 days, however, the number of coughs in the AM group 
was 19 Z)Z 5. The number of sputum samples produced over 
the 6 h observation period was also significantly reduced 
(P<O.Ol) for all 12 patients following 7 days treatment with 
antibiotics. The sputum wet weights reflected the coughs, 
namely from 4.2 i 0.6 to 2.2 f 0.9 g for the AM group at 
baseline and 7 days and from 2.3 f 1.1 to 0.6 * 0.5 g for the 
CP group at the two respective time points. However, the 
sputum at 30 days in the AM group was 3.6 & 2.1 g. 
Figure 3 shows the amount of sputum produced by each 
patient during 24 h prior to baseline and 7 day assessments 
[Fig. 3(a)] and for those patients who were assessed at 
30 days [Fig. 3(b)]. The amount of sputum produced 
following 7 days of treatment was significantly reduced 
(P<O.Ol) compared with baseline. 
Discussion 
Antibiotics are widely used as a treatment for exacerbations 
of chronic obstructive pulmonary disease (6,24). They 
appear to offer a range of beneficial effects. There is specific 
evidence that even modest concentrations of amoxycillin or 
of ciprofloxacin can help to limit disruption of epithelial 
integrity, lessening damage to epithelial cells, lessening 
loss of cilia and helping to maintain ciliary beat frequency 
(25). 
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FIG. 3. Sputum production in 24 h: (a) at baseline and at 
7 days in all patients; (b) at baseline, 7 days and 30 days 
in all patients (five AM; one CP) who completed the 
follow-up assessment. 
Baseline mucociliary clearance was lower in the CP than 
in the AM group, possibly because of their lower frequency 
of coughing. Even unproductive coughing can enhance 
movement of lung secretions (26). The lower baseline of the 
CP group may have left more ‘scope’ for improvement 
in their response to antibiotic treatment. Certainly this 
group appears to show a greater clearance improvement 
than the AM-treated group. Moreover, these CP patients 
also showed a decreased frequency of cough (WO.05) on 
antibiotic treatment. Given that cough events - productive 
or non-productive - probably contributed substantially 
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to their baseline clearance, their apparently reduced 
dependence on clearance by cough may imply some 
actual enhancement of their ‘true’ mucociliary clearance. 
Clinically the effect of CP treatment in reducing cough 
frequency may of itself be beneficial specifically by reducing 
the risk of cough-mediated damage to the ciliated epi- 
thelium. Even when free from exacerbation, COPD patients 
have grossly abnormal airways epithelium. Avoidance of 
too much further damage to this already damaged lung 
defence mechanism may be crucial to maintaining even a 
minimally adequate airway defence. 
Our data primarily look at a short-term effect of 
treatment. Restoration to ‘normal’ of the mucociliary 
mechanism after an acute insult may, however, take much 
longer than 1 week. Recovery of clearance from the effect 
of influenza A appears to take some 3 months (27). 
Mycoplasma pneumoniae may cause a clearance reduction 
lasting for as long as 1 yr (28). Similarly restoration of 
clearance to normal following cessation of smoking by 
asymptomatic smokers requires some 2-3 months (29). 
Thus our data 1 week after start of treatment can, at best, 
characterize only a stage in the patients’ progress. Never- 
theless, although only a very modest (and statistically 
insignificant) clearance enhancement was observed, there 
was at least no further deterioration from the patients’ 
baseline levels measured just before treatment. 
However, our patients’ progress over the following 
few weeks was undoubtedly disappointing, with three 
experiencing significant further exacerbation and two oth- 
ers requiring additional treatment. Data from the patients 
who attended for 30 day follow-up study were also dis- 
appointing with no evidence of any further improvement of 
tracheobronchial clearance together with a cough frequency 
back to the pretreatment level. A very obvious possible 
implication is that a 7 day antibiotic course may simply not 
be long enough for such patients as these or that the dosage 
level achieved may have been inadequate. Certainly our 
study suggests that COPD patients require at least close 
observation over the weeks following a standard 7 day 
course of antibiotic treatment for exacerbation. 
All the patients studied had long-established COPD and 
were receiving a wide range of bronchodilator and cortico- 
steroid therapy. With their long history of disease, each 
will have experienced a long sequence of events damaging 
to their ciliated epithelium and its mucociliary defence 
capability. It is hardly surprising that such patients are 
prone to infective exacerbation and the role of short-term 
treatment is one of damage limitation. The 7 day antibiotic 
treatment led only to a slight apparent improvement of 
tracheobronchial clearance. Nevertheless, the improvement 
characterized by the patients’ retention curves (Fig. 1) may 
be an underestimate of the true gain. The significant 
reduction seen in sputum production may also have meant 
a substantial decrease in the proportion of airways mucus 
clearance achieved by cough rather than by mucociliary 
transport mechanisms. Taken together, slightly improved 
tracheobronchial clearance and significantly decreased 
cough suggested a significant role of the antibiotic treat- 
ment at least in lessening the risks of further and greater 
damage to the airway epithelium. 
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